StockData
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. (SRPT) stock

SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.77−0.36 (-2.38%)

Close on Nov 17, 2026Market cap $1.56BP/E –Yield –

Sarepta Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Sarepta Therapeutics's pe ratio was 43.7× on Jul 31, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 202643.7×+17.0
2025Apr 30, 202526.7×−73.0
2024Dec 31, 202499.7×–

More Sarepta Therapeutics figures

See a number that looks wrong?